ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.29 per share a year ago.